Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
L. Casares, R. Moreno, M. Higgins…·L. de la Vega
This study identifies CDDO-derivatives as BACH1 inhibitors, explaining their higher potency as HMOX1 inducers compared to CDDO.
D. G. Ryan, E. V. Knatko, A. Casey…·A. T. Dinkova-Kostova
This study shows Nrf2 regulates macrophage metabolism, redox balance, and inflammatory responses, with 4-OI modulating these effects through Nrf2.
F. Inesta-Vaquera, P. Navasumrit, C. J. Henderson…·C. R. Wolf
This study uses Hmox1 reporter mice to demonstrate iAs-induced oxidative stress and validate N-acetyl cysteine as a potential therapy for arsenic toxicity.
L. Casares, J. D. Unciti, M. E. Prados…·L. de la Vega
The paper develops a CBD derivative with dual BACH1 inhibition and NRF2 activation, showing neuroprotection in Huntington's disease cell models.
L. Torrente, G. Maan, L. Casares…·L. de la Vega
The paper identifies AT9283 as a drug that selectively kills colorectal cancer cells with hyperactive NRF2, showing its potential as a therapeutic target.
R. Moreno, S. Banerjee, A. W. Jackson…·L. de la Vega
This study identifies DYRK2 as a kinase that phosphorylates HSF1, enhancing its activity and promoting resistance to proteotoxic stress in TNBC, with implications for therapeutic targeting.